Literature DB >> 19276197

Behaviour of polyester grafts in adult patients with repaired coarctation of the aorta.

Els Troost1, Marc Gewillig, Willem Daenen, Bart Meyns, Jan Bogaert, Kristien Van Deyk, Werner Budts.   

Abstract

AIMS: Whatever the technique used for surgical or endovascular repair of a coarctation of the aorta (CA), long-term complications might occur. Aneurysm formation after patch angioplasty is not uncommon and may lead to a life-threatening condition. Therefore, we were interested in the long-term results of different types of tube grafts, from which a lower degree of dilatation is expected. METHODS AND
RESULTS: All patients, currently older than 16 years, who underwent (redo) surgery for CA, and in whom a tube graft was inserted, were selected from the database of congenital heart disease of our hospital. Follow-up data were collected by reviewing the patients' files. The degree of graft dilatation was calculated for each patient. Fifty-three patients (41 males, median age 33.1 years, Q1-Q3 29.9-40.2 years) could be included in the study, in which 20 (38%) 'Gelseal', 12 (23%) 'Gelsoft', 8 (15%) 'Gelweave', and 13 (24%) older types of grafts were used. Twenty patients underwent a primary repair and in all others a tube graft was implanted after a previous patch angioplasty. The median graft diameter (manufacturer size) at implantation was 20 mm (Q1-Q3 16-22 mm). The median follow-up time of the grafts was 13.1 years (Q1-Q3 9.0-17.2 years). The graft size increased to a median value of 26 mm (Q1-Q3 22-30 mm) (median 50% increase in diameter, range 0-271%, P < 0.0001). The diameter of six grafts remained unchanged during follow-up. Three deaths occurred, of whom two were cardiac-related. False aneurysms occurred in four patients, graft aneurysm in two, endarteritis in two, and graft stenosis in one.
CONCLUSION: Nearly, all tube grafts dilated up to 50% of the manufacturer diameter during follow-up. Re-interventions were inevitable in more than 10 per cent of the cases, primarily because of (false) aneurysm formation. Our series illustrates that late complications are not uncommon, so that rigorous follow-up of these CA patients remains mandatory.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19276197     DOI: 10.1093/eurheartj/ehp054

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  6 in total

Review 1.  Dynamics of proteins in Golgi membranes: comparisons between mammalian and plant cells highlighted by photobleaching techniques.

Authors:  T H Ward; F Brandizzi
Journal:  Cell Mol Life Sci       Date:  2004-01       Impact factor: 9.261

Review 2.  [Heart valve and myocardial tissue engineering].

Authors:  Serghei Cebotari; Igor Tudorache; Tobias Schilling; Axel Haverich
Journal:  Herz       Date:  2010-08       Impact factor: 1.443

Review 3.  Old Myths, New Concerns: the Long-Term Effects of Ascending Aorta Replacement with Dacron Grafts. Not All That Glitters Is Gold.

Authors:  Cristiano Spadaccio; Francesco Nappi; Nawwar Al-Attar; Fraser W Sutherland; Christophe Acar; Antonio Nenna; Marcella Trombetta; Massimo Chello; Alberto Rainer
Journal:  J Cardiovasc Transl Res       Date:  2016-05-31       Impact factor: 4.132

4.  Dacron Tube Graft-Covered Stenting of Recoarctation of the Aorta.

Authors:  Vimalarani Arulselvam; Neale Nicola Kalis; Saud Rashid Al Amer; Shereen Al Shaik
Journal:  Heart Views       Date:  2018 Jan-Mar

5.  Necessity of life-long follow-up after surgery for coarctation of the aorta: a case series of very late false aneurysm formation.

Authors:  Tim Somers; Hedwig M J M Nies; Roland R J van Kimmenade; Dennis G H Bosboom; Guillaume S C Geuzebroek; Wim J Morshuis
Journal:  Eur Heart J Case Rep       Date:  2022-02-16

Review 6.  Management of adults with coarctation of aorta.

Authors:  Pradyumna Agasthi; Sai Harika Pujari; Andrew Tseng; Joseph N Graziano; Francois Marcotte; David Majdalany; Farouk Mookadam; Donald J Hagler; Reza Arsanjani
Journal:  World J Cardiol       Date:  2020-05-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.